Intracellular islatravir pharmacology differs between species in an in vitro model: implications for preclinical study design
Open Access
- 2 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (4) , 1000-1004
Abstract
Islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine; EFdA) is a first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) being investigated for HIV treatment and prevention. EFdA is intracellularly phosphorylated to EFdA-triphosphate (EFdA-tp), a competitive substrate of deoxyadenosine-triphosphate (dATP). Thus, translating safety and efficacy findings from preclinical studies relies on the assumption that EFdA’s intracellular pharmacology can be extrapolated across species. We investigated how EFdA is phosphorylated across animal species commonly used for preclinical models in drug development to identify those that most closely matched humans. PBMCs were isolated from whole blood of six species (human, rhesus macaque non-human primate (rmNHP), rat, minipig, dog, and rabbit) using Ficoll separation and counted on a haemocytometer by Trypan blue staining. One million live cells were cultured in media supplemented with 10 U/mL human IL-2, 10% FBS and 1% antibiotics and treated with 0, 17, 170, and 1700 nM EFdA (n = 3 replicates per concentration). After 24 h, representative cell counts were derived from untreated control wells (as above), cells were washed in PBS, and lysed with 70:30 methanol:water. EFdA-tp and dATP concentrations were quantified by HPLC-MS/MS and normalized to the representative live cell counts for each species. When compared to human values, EFdA-tp concentrations for each EFdA treatment concentration were lower in all species (rmNHP 1.5–2.1-fold, rat 4.5–15-fold, minipig 37–71-fold, dog and rabbit >100-fold). Additionally, rmNHP and dog PBMCs exhibited significantly higher (7–10-fold; P < 0.001) dATP when compared with human PBMCs. Given intracellular pharmacology differences, these preclinical models may be a conservative estimate of EFdA’s intracellular pharmacokinetics and efficacy in humans.Keywords
Funding Information
- U.S. President’s Emergency Plan for AIDS Relief (AID-OAA-A-17-00011, AID-OAA-A-14-00012)
- USAID
- CFAR
- NIH (P30 AI050410)
This publication has 14 references indexed in Scilit:
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591Current Opinion in HIV and AIDS, 2018
- Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissuesJournal of Antimicrobial Chemotherapy, 2017
- Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)Proceedings of the National Academy of Sciences of the United States of America, 2016
- Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal TissueAIDS Research and Human Retroviruses, 2013
- Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase InhibitorsJournal of Virology, 2011
- 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variantsThe International Journal of Biochemistry & Cell Biology, 2008
- Porcine peripheral blood dendritic cells and natural interferon‐producing cellsImmunology, 2003
- Ways to Fit a PK Model with Some Data Below the Quantification LimitJournal of Pharmacokinetics and Pharmacodynamics, 2001
- Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2?-deoxyadenosineCancer Chemotherapy and Pharmacology, 1995
- Dog Lymphocyte Cultures Facilitate the Isolation and Growth of Virulent Canine Distemper VirusJournal of Veterinary Diagnostic Investigation, 1992